Close to getting his PhD, Jake Becraft was wondering what he should do with his career–and then a friend called with a PowerPoint. Becraft was at the Massachusetts Institute of Technology, completing ...
Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced the promotion of Prashant Nambiar, DVM, PhD, MBA, as Chief Scientific Officer and appointment of Ethan Cash as ...
-- Financing oversubscribed; proceeds from the round will be used to expand Strand’s growing mRNA platforms into multiple immuno-oncology and disease settings, and advance lead drug into Phase 1 ...
Strand Therapeutics has added to its series A funding from last year, bringing the total to $97 million. The messenger RNA (mRNA) therapeutics company is gearing up to bring its lead drug candidate, ...
Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced that Jake Becraft, PhD, Co-founder and Chief Executive Officer, will present at the 44th Annual J.P. Morgan ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Strand Therapeutics, a privately held biotech company developing next-generation, programmable mRNA therapeutics beyond vaccines, today announced that the company ...
Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced that former Nimbus Therapeutics CEO, Jeb Keiper, has joined Strand’s Board as an independent Director to ...
Leader in mRNA therapeutics strengthens clinical development expertise with globally recognized oncology innovator Strand Therapeutics, the leader in programmable mRNA medicines, today announced the ...
Creative Biolabs optimizes the mRNA drug development model by integrating sequence design, RNA-protein interaction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback